Course: Outcomes of COVID-19 and Vaccination in Patients With Moderate to Severe Atopic Dermatitis Treated With Tralokinumab
CME Credits: 1.00
Released: 2022-10-12
Atopic dermatitis (AD) is an inflammatory skin disorder mainly caused by Th2 cytokines, especially interleukin (IL) 13. Tralokinumab, an IgG4 monoclonal antibody that neutralizes IL-13, has demonstrated safety and efficacy in clinical trials for treatment of adults with moderate to severe AD., Concerns arose during the COVID-19 pandemic that immunomodulatory drugs may increase disease susceptibility or severity or interfere with SARS-CoV-2 vaccination. The aim of the study was to assess outcomes of COVID-19 and SARS-CoV-2 vaccination among adult patients with AD treated with tralokinumab in the ECZTEND trial ().
Educational Objective
To identify the key insights or developments described in this article
View Full Course